You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameRescinnamine
Accession NumberDB01180  (APRD00112)
TypeSmall Molecule
GroupsApproved
DescriptionRescinnamine is an angiotensin-converting enzyme inhibitor used as an antihypertensive drug. It is an alkaloid obtained from Rauwolfia serpentina and other species of Rauwolfia. [Wikipedia]
Structure
Thumb
Synonyms
3,4,5-Trimethoxycinnamoyl methyl reserpate
Rescinnamine
Trimethoxy cinnamoyl reserpate de methyl
Tsuruselpi S
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Tsuruselpi SNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIQ6W1F7DJ2D
CAS number24815-24-5
WeightAverage: 634.716
Monoisotopic: 634.289030952
Chemical FormulaC35H42N2O9
InChI KeySZLZWPPUNLXJEA-QEGASFHISA-N
InChI
InChI=1S/C35H42N2O9/c1-40-21-8-9-22-23-11-12-37-18-20-15-29(46-30(38)10-7-19-13-27(41-2)33(43-4)28(14-19)42-3)34(44-5)31(35(39)45-6)24(20)17-26(37)32(23)36-25(22)16-21/h7-10,13-14,16,20,24,26,29,31,34,36H,11-12,15,17-18H2,1-6H3/b10-7+/t20-,24+,26-,29-,31+,34+/m1/s1
IUPAC Name
methyl (1R,15S,17R,18R,19S,20S)-6,18-dimethoxy-17-{[3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]oxy}-3,13-diazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-2(10),4(9),5,7-tetraene-19-carboxylate
SMILES
[H][C@]12C[C@@H](OC(=O)C=CC3=CC(OC)=C(OC)C(OC)=C3)[[email protected]](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2
Pharmacology
IndicationFor the treatment of hypertension.
Structured Indications Not Available
PharmacodynamicsUsed to treat hypertension. Rescinnamine inhibits angiotensin-converting enzyme. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex and general vasoconstriction, both of which lead to increases vascular resistance. By inhibiting angiotensin II, aldosterone reabsorption is decreased as well as vasoconstriction. This combined effect serves to decrease blood pressure.
Mechanism of actionRescinnamine Binds to and inhibits the angiotensin converting enzyme. Rescinnamine competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. Inhibition of ACE results in decreased plasma angiotensin II. As angiotensin II is a vasoconstrictor and a negative-feedback mediator for renin activity, lower concentrations result in a decrease in blood pressure and stimulation of baroreceptor reflex mechanisms, which leads to decreased vasopressor activity and to decreased aldosterone secretion.
TargetKindPharmacological actionActionsOrganismUniProt ID
Angiotensin-converting enzymeProteinyes
inhibitor
HumanP12821 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Rescinnamine Action PathwayDrug actionSMP00155
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Rescinnamine.Experimental
AcebutololAcebutolol may increase the hypotensive activities of Rescinnamine.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Aceclofenac.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Acetovanillone.Investigational
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Rescinnamine.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Adapalene.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Rescinnamine.Approved, Investigational
AliskirenAliskiren may increase the hyperkalemic activities of Rescinnamine.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Rescinnamine.Approved
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Rescinnamine.Approved
AlprenololAlprenolol may increase the hypotensive activities of Rescinnamine.Approved, Withdrawn
AmbrisentanRescinnamine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineRescinnamine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideAmiloride may increase the hyperkalemic activities of Rescinnamine.Approved
Aminosalicylic AcidAminosalicylic Acid may decrease the antihypertensive activities of Rescinnamine.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Rescinnamine.Approved
AnisodamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Antipyrine.Approved
ApremilastThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Apremilast.Approved, Investigational
AprotininAprotinin may decrease the antihypertensive activities of Rescinnamine.Approved, Withdrawn
ArdeparinArdeparin may increase the hyperkalemic activities of Rescinnamine.Approved, Withdrawn
AtenololAtenolol may increase the hypotensive activities of Rescinnamine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Rescinnamine.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Azapropazone.Withdrawn
AzathioprineRescinnamine may increase the myelosuppressive activities of Azathioprine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Rescinnamine.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Balsalazide.Approved, Investigational
BemiparinBemiparin may increase the hyperkalemic activities of Rescinnamine.Approved
BenazeprilBenazepril may increase the hypotensive activities of Rescinnamine.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Rescinnamine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Rescinnamine.Withdrawn
BenoxaprofenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Benoxaprofen.Withdrawn
BepridilBepridil may increase the hypotensive activities of Rescinnamine.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Rescinnamine.Approved
BethanidineBethanidine may increase the hypotensive activities of Rescinnamine.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Betulinic Acid.Investigational
BimatoprostBimatoprost may increase the hypotensive activities of Rescinnamine.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Rescinnamine.Approved
BosentanBosentan may increase the hypotensive activities of Rescinnamine.Approved, Investigational
BretyliumBretylium may increase the hypotensive activities of Rescinnamine.Approved
BrimonidineBrimonidine may increase the hypotensive activities of Rescinnamine.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Rescinnamine.Approved
BromfenacThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Bucillamine.Investigational
BumetanideBumetanide may increase the hypotensive activities of Rescinnamine.Approved
BupranololBupranolol may increase the hypotensive activities of Rescinnamine.Approved
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Rescinnamine.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Rescinnamine.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Rescinnamine.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Rescinnamine.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Rescinnamine.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Rescinnamine.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Rescinnamine.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the hypotensive activities of Rescinnamine.Approved, Investigational
CertoparinCertoparin may increase the hyperkalemic activities of Rescinnamine.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Rescinnamine.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Rescinnamine.Approved
CilazaprilCilazapril may increase the hypotensive activities of Rescinnamine.Approved
CiprofloxacinRescinnamine may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
ClonidineClonidine may increase the hypotensive activities of Rescinnamine.Approved
ClonixinThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Clonixin.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Rescinnamine.Approved
CurcuminThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Curcumin.Investigational
CyclothiazideCyclothiazide may increase the hypotensive activities of Rescinnamine.Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Rescinnamine is combined with D-Limonene.Investigational
DalteparinDalteparin may increase the hyperkalemic activities of Rescinnamine.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Rescinnamine.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Rescinnamine.Approved
dersalazinedersalazine may decrease the antihypertensive activities of Rescinnamine.Investigational
DeserpidineDeserpidine may increase the hypotensive activities of Rescinnamine.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Rescinnamine.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Diclofenac.Approved, Vet Approved
DiflunisalDiflunisal may decrease the antihypertensive activities of Rescinnamine.Approved
DihydralazineRescinnamine may increase the hypotensive activities of Dihydralazine.Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Rescinnamine.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Rescinnamine.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Rescinnamine.Approved
DrospirenoneRescinnamine may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Rescinnamine is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Ebselen.Investigational
EfonidipineEfonidipine may increase the hypotensive activities of Rescinnamine.Approved
EnalaprilEnalapril may increase the hypotensive activities of Rescinnamine.Approved, Vet Approved
EnalaprilatEnalaprilat may increase the hypotensive activities of Rescinnamine.Approved
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Rescinnamine.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Rescinnamine.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Rescinnamine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Rescinnamine.Approved
Etacrynic acidEtacrynic acid may increase the hypotensive activities of Rescinnamine.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Etanercept.Approved, Investigational
EtodolacThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Evening primrose oil.Approved
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Rescinnamine.Approved
exisulindThe risk or severity of adverse effects can be increased when Rescinnamine is combined with exisulind.Investigational
FelodipineFelodipine may increase the hypotensive activities of Rescinnamine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Fenbufen.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Rescinnamine.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Fenoprofen.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Floctafenine.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Flunixin.Vet Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Flurbiprofen.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Rescinnamine.Experimental
FosinoprilFosinopril may increase the hypotensive activities of Rescinnamine.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Rescinnamine.Approved, Vet Approved
FurosemideFurosemide may increase the hypotensive activities of Rescinnamine.Approved, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of Rescinnamine.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Rescinnamine.Approved
GuanethidineGuanethidine may increase the hypotensive activities of Rescinnamine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Rescinnamine.Approved, Investigational
HeparinHeparin may increase the hyperkalemic activities of Rescinnamine.Approved, Investigational
HexamethoniumHexamethonium may increase the hypotensive activities of Rescinnamine.Experimental
HigenamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Higenamine.Investigational
HMPL-004The risk or severity of adverse effects can be increased when Rescinnamine is combined with HMPL-004.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Rescinnamine.Approved
HydralazineHydralazine may increase the hypotensive activities of Rescinnamine.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Rescinnamine.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Rescinnamine.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Ibuproxam.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Rescinnamine.Approved
IloprostIloprost may increase the hypotensive activities of Rescinnamine.Approved, Investigational
ImidaprilRescinnamine may increase the hypotensive activities of Imidapril.Investigational
IndapamideIndapamide may increase the hypotensive activities of Rescinnamine.Approved
IndenololIndenolol may increase the hypotensive activities of Rescinnamine.Withdrawn
IndomethacinThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Indoprofen.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Rescinnamine.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Rescinnamine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Rescinnamine.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Rescinnamine.Approved, Investigational
IronThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Iron.Approved
Iron DextranThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Iron Dextran.Approved, Vet Approved
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Rescinnamine.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Isoxicam.Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Rescinnamine.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Kebuzone.Experimental
KetanserinRescinnamine may increase the hypotensive activities of Ketanserin.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Ketorolac.Approved
LabetalolLabetalol may increase the hypotensive activities of Rescinnamine.Approved
LacidipineLacidipine may increase the hypotensive activities of Rescinnamine.Approved
Lanthanum carbonateThe serum concentration of Rescinnamine can be decreased when it is combined with Lanthanum carbonate.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Rescinnamine.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Leflunomide.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Rescinnamine.Approved, Investigational
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Rescinnamine.Approved
LisinoprilLisinopril may increase the hypotensive activities of Rescinnamine.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Rescinnamine.Approved
LofexidineLofexidine may increase the hypotensive activities of Rescinnamine.Approved, Investigational
LornoxicamThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Rescinnamine.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Loxoprofen.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Lumiracoxib.Approved, Investigational
MacitentanRescinnamine may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Magnesium salicylate.Approved
ManidipineManidipine may increase the hypotensive activities of Rescinnamine.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Masoprocol.Approved
MebanazineMebanazine may increase the hypotensive activities of Rescinnamine.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Rescinnamine.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Mefenamic acid.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Meloxicam.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Rescinnamine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Metamizole.Withdrawn
MethyclothiazideMethyclothiazide may increase the hypotensive activities of Rescinnamine.Approved
MethyldopaMethyldopa may increase the hypotensive activities of Rescinnamine.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Rescinnamine.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Rescinnamine.Approved, Investigational
MetipranololMetipranolol may increase the hypotensive activities of Rescinnamine.Approved
MetolazoneMetolazone may increase the hypotensive activities of Rescinnamine.Approved
MetoprololMetoprolol may increase the hypotensive activities of Rescinnamine.Approved, Investigational
MetyrosineRescinnamine may increase the hypotensive activities of Metyrosine.Approved
MibefradilMibefradil may increase the hypotensive activities of Rescinnamine.Withdrawn
MinaprineMinaprine may increase the hypotensive activities of Rescinnamine.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Rescinnamine.Approved
MizoribineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Rescinnamine.Approved
MoexiprilMoexipril may increase the hypotensive activities of Rescinnamine.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Rescinnamine.Approved
MoxonidineMoxonidine may increase the hypotensive activities of Rescinnamine.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Nabumetone.Approved
NadololNadolol may increase the hypotensive activities of Rescinnamine.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Rescinnamine.Approved
NafamostatThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Naftifine.Approved
NaftopidilRescinnamine may increase the hypotensive activities of Naftopidil.Investigational
NaproxenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Naproxen.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when Rescinnamine is combined with NCX 4016.Investigational
NebivololNebivolol may increase the hypotensive activities of Rescinnamine.Approved, Investigational
NepafenacThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Nepafenac.Approved
NialamideNialamide may increase the hypotensive activities of Rescinnamine.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Rescinnamine.Approved
NicorandilNicorandil may increase the hyperkalemic activities of Rescinnamine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Niflumic Acid.Approved
NiguldipineNiguldipine may increase the hypotensive activities of Rescinnamine.Experimental
NilvadipineNilvadipine may increase the hypotensive activities of Rescinnamine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Nimesulide.Approved, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Rescinnamine.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Rescinnamine.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Rescinnamine.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Rescinnamine.Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Rescinnamine.Approved
ObinutuzumabRescinnamine may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Rescinnamine.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Rescinnamine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Olsalazine.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Rescinnamine.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Orgotein.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Oxaprozin.Approved
OxprenololOxprenolol may increase the hypotensive activities of Rescinnamine.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Oxyphenbutazone.Withdrawn
ParecoxibThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Rescinnamine.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Rescinnamine.Approved
PenbutololPenbutolol may increase the hypotensive activities of Rescinnamine.Approved, Investigational
PentoliniumPentolinium may increase the hypotensive activities of Rescinnamine.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Rescinnamine.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Rescinnamine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Rescinnamine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Rescinnamine.Withdrawn
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Rescinnamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Rescinnamine.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Rescinnamine.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Pimecrolimus.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Rescinnamine.Withdrawn
PindololPindolol may increase the hypotensive activities of Rescinnamine.Approved
PiretanidePiretanide may increase the hypotensive activities of Rescinnamine.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Pirfenidone.Investigational
PirlindolePirlindole may increase the hypotensive activities of Rescinnamine.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Piroxicam.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Rescinnamine.Withdrawn
PolythiazidePolythiazide may increase the hypotensive activities of Rescinnamine.Approved
PrazosinPrazosin may increase the hypotensive activities of Rescinnamine.Approved
PregabalinThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Pregabalin.Approved, Illicit, Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Propacetamol.Approved
PropranololPropranolol may increase the hypotensive activities of Rescinnamine.Approved, Investigational
PTC299The risk or severity of adverse effects can be increased when Rescinnamine is combined with PTC299.Investigational
QuinaprilQuinapril may increase the hypotensive activities of Rescinnamine.Approved, Investigational
QuinethazoneQuinethazone may increase the hypotensive activities of Rescinnamine.Approved
QuinineQuinine may increase the hypotensive activities of Rescinnamine.Approved
RamiprilRamipril may increase the hypotensive activities of Rescinnamine.Approved
RasagilineRasagiline may increase the hypotensive activities of Rescinnamine.Approved
RemikirenRemikiren may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Resveratrol.Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Rescinnamine.Approved
RilmenidineRescinnamine may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatRescinnamine may increase the hypotensive activities of Riociguat.Approved
RituximabRescinnamine may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Rofecoxib.Investigational, Withdrawn
SacubitrilThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Rescinnamine.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Salicylamide.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Rescinnamine.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Rescinnamine.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Rescinnamine.Investigational
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Rescinnamine.Approved
SelegilineSelegiline may increase the hypotensive activities of Rescinnamine.Approved, Investigational, Vet Approved
SelexipagSelexipag may increase the hypotensive activities of Rescinnamine.Approved
SeratrodastThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Seratrodast.Approved, Investigational
SildenafilSildenafil may increase the antihypertensive activities of Rescinnamine.Approved, Investigational
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Rescinnamine.Approved, Investigational
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Rescinnamine.Approved, Investigational
SitaxentanRescinnamine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Sodium aurothiomalate.Approved
SpiraprilSpirapril may increase the hypotensive activities of Rescinnamine.Approved
SpironolactoneSpironolactone may increase the hyperkalemic activities of Rescinnamine.Approved
SRT501The risk or severity of adverse effects can be increased when Rescinnamine is combined with SRT501.Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Sulindac.Approved
SuprofenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Suprofen.Approved, Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Rescinnamine.Approved, Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Rescinnamine.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Rescinnamine.Approved, Investigational
TemocaprilTemocapril may increase the hypotensive activities of Rescinnamine.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Rescinnamine.Approved
TenoxicamThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Teriflunomide.Approved
TerlipressinTerlipressin may increase the hypotensive activities of Rescinnamine.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Tiaprofenic acid.Approved
TiboloneTibolone may increase the hypotensive activities of Rescinnamine.Approved
TicrynafenTicrynafen may increase the hypotensive activities of Rescinnamine.Withdrawn
TimololTimolol may increase the hypotensive activities of Rescinnamine.Approved
TinoridineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Rescinnamine.Approved
TizanidineTizanidine may increase the hypotensive activities of Rescinnamine.Approved
TolazolineTolazoline may increase the hypotensive activities of Rescinnamine.Approved, Vet Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Tolmetin.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Rescinnamine.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Rescinnamine.Approved
TorasemideTorasemide may increase the hypotensive activities of Rescinnamine.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Rescinnamine.Approved
TranilastThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Rescinnamine.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Rescinnamine.Approved
TravoprostTravoprost may increase the hypotensive activities of Rescinnamine.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Rescinnamine.Approved, Investigational
TriamtereneTriamterene may increase the hyperkalemic activities of Rescinnamine.Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Rescinnamine.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Rescinnamine.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Rescinnamine.Approved
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Rescinnamine.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Trisalicylate-choline.Approved
UdenafilUdenafil may increase the antihypertensive activities of Rescinnamine.Approved, Investigational
UnoprostoneUnoprostone may increase the hypotensive activities of Rescinnamine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Valdecoxib.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Rescinnamine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Rescinnamine.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Rescinnamine.Approved, Investigational
VinpocetineRescinnamine may increase the hypotensive activities of Vinpocetine.Investigational
XylometazolineXylometazoline may increase the hypotensive activities of Rescinnamine.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Rescinnamine.Approved, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Zileuton.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Zomepirac.Withdrawn
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesC02AA01C02LA02C02LA52
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (52.7 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9604
Blood Brain Barrier+0.9248
Caco-2 permeable+0.6805
P-glycoprotein substrateSubstrate0.8163
P-glycoprotein inhibitor IInhibitor0.8826
P-glycoprotein inhibitor IINon-inhibitor0.6553
Renal organic cation transporterInhibitor0.5
CYP450 2C9 substrateNon-substrate0.8706
CYP450 2D6 substrateNon-substrate0.9064
CYP450 3A4 substrateSubstrate0.7223
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9144
CYP450 3A4 inhibitorNon-inhibitor0.8203
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7162
Ames testNon AMES toxic0.9208
CarcinogenicityNon-carcinogens0.9453
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.8345 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.697
hERG inhibition (predictor II)Non-inhibitor0.678
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point238.5 °CPhysProp
logP3.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00349 mg/mLALOGPS
logP4.48ALOGPS
logP4.07ChemAxon
logS-5.3ALOGPS
pKa (Strongest Acidic)16.29ChemAxon
pKa (Strongest Basic)7.56ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area117.78 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity171.16 m3·mol-1ChemAxon
Polarizability69.65 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (13.2 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as yohimbine alkaloids. These are alkaloids containing the pentacyclic yohimban skeleton. The Yohimbinoid alkaloids contain a carbocyclic ring E arising through C-17 to C-18 bond formation in a corynantheine precursor.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassYohimbine alkaloids
Sub ClassNot Available
Direct ParentYohimbine alkaloids
Alternative Parents
Substituents
  • Yohimbine
  • Corynanthean skeleton
  • Yohimbine alkaloid
  • Pyridoindole
  • Beta-carboline
  • Cinnamic acid ester
  • Coumaric acid or derivatives
  • Cinnamic acid or derivatives
  • Phenylpropene
  • Indole or derivatives
  • Indole
  • Methoxybenzene
  • Styrene
  • Phenol ether
  • Anisole
  • Aralkylamine
  • Fatty acid ester
  • Alkyl aryl ether
  • Fatty acyl
  • Benzenoid
  • Piperidine
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Alpha,beta-unsaturated carboxylic ester
  • Enoate ester
  • Methyl ester
  • Pyrrole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxylic acid ester
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Dialkyl ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety.
Gene Name:
ACE
Uniprot ID:
P12821
Molecular Weight:
149713.675 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Azhar I, Mazhar F, Manzar QN, Hussain I, Shamim S: Colorimetric determination of indolic drugs. Pak J Pharm Sci. 2005 Apr;18(2):48-51. [PubMed:16431399 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23